early detection
Gene Variant Test Shows Promise for Improving Accuracy of CA19-9 for Pancreatic Cancer Detection
Premium
Investigators are assessing performance in a prospective cohort with hopes that the method can be used to complement currently used imaging surveillance.
Harbinger Health Raises $140 Million in Series B Financing
The firm said the funds will enable completion of clinical validation of its first blood-based cancer screening product ahead of an anticipated 2025 launch.
The firm said its DNA methylation testing technology could be applied to dozens of cancers and potentially some non-cancer chronic diseases.
The firm is offering its epiCervix assay in the US as a laboratory-developed test to be used alongside human papillomavirus screening.
Recent meeting presentations have offered a first look at the company's targeted methylation approach and the test's high sensitivity in early-stage cancers.